Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glycine propionyl-L-carnitine is a dietary supplement consisting of a molecularly bonded combination of propionyl-L-carnitine and the amino acid glycine. It acts as a prodrug, leading to increased levels of glycine, carnitine, and propionic acid in the body. Its main investigated effects are as a nitric oxide stimulant (increasing blood nitrate/nitrite, a surrogate marker of nitric oxide), antioxidant (reducing lipid peroxidation), and as a potential ergogenic aid to enhance anaerobic power output and reduce exercise-related lactate buildup. Research suggests its vasodilatory and potential antioxidant properties may improve blood flow and reduce oxidative stress during and after strenuous exercise. GPLC is mainly marketed and used as a dietary supplement, especially among athletes and those aiming to improve exercise performance or vascular health[1][5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glycine propionyl-L-carnitine.